- Home
- MRBK vs PLX Comparison
MRBK vs PLX Comparison
Compare MRBK & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRBK
- PLX
- Stock Information
- Founded
- MRBK 2004
- PLX 1993
- Country
- MRBK United States
- PLX United States
- Employees
- MRBK N/A
- PLX N/A
- Industry
- MRBK Major Banks
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRBK Finance
- PLX Health Care
- Exchange
- MRBK Nasdaq
- PLX Nasdaq
- Market Cap
- MRBK 145.8M
- PLX 122.6M
- IPO Year
- MRBK 2017
- PLX 1998
- Fundamental
- Price
- MRBK $14.32
- PLX $1.46
- Analyst Decision
- MRBK Buy
- PLX Strong Buy
- Analyst Count
- MRBK 2
- PLX 1
- Target Price
- MRBK $17.00
- PLX $15.00
- AVG Volume (30 Days)
- MRBK 124.9K
- PLX 1.3M
- Earning Date
- MRBK 07-29-2025
- PLX 08-13-2025
- Dividend Yield
- MRBK 3.51%
- PLX N/A
- EPS Growth
- MRBK 33.85
- PLX N/A
- EPS
- MRBK 1.42
- PLX 0.05
- Revenue
- MRBK $101,096,000.00
- PLX $59,764,000.00
- Revenue This Year
- MRBK $22.49
- PLX $65.02
- Revenue Next Year
- MRBK $9.50
- PLX $57.34
- P/E Ratio
- MRBK $10.06
- PLX $30.21
- Revenue Growth
- MRBK 8.82
- PLX 0.18
- 52 Week Low
- MRBK $10.04
- PLX $0.82
- 52 Week High
- MRBK $17.33
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- MRBK 66.65
- PLX 46.02
- Support Level
- MRBK $13.65
- PLX $1.36
- Resistance Level
- MRBK $14.33
- PLX $1.54
- Average True Range (ATR)
- MRBK 0.43
- PLX 0.08
- MACD
- MRBK 0.11
- PLX 0.02
- Stochastic Oscillator
- MRBK 98.37
- PLX 41.67
About MRBK Meridian Corporation
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.